Proteomics Core

蛋白质组学核心

• 批准号: 10674960
• 负责人: Lauren Elizabeth Ball
• 金额: $ 27.18万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10674960
• 关键词: Acetylation; Address; Advanced Development; Agreement; Applications Grants; Arginine; Award; Bioinformatics; Biological Markers; Biology; Cancer Center Support Grant; Cells; Centers of Research Excellence; Complement; Computer software; Consult; Consultations; Cysteine; Data Analyses; Dedications; Detection; Development; Disease; Disease Progression; Dissociation; Drug resistance; Education; Electron Transport; Ensure; Enzymes; Equilibrium; Evaluation; Experimental Designs; Faculty; Freezing; Goals; Grant; Human Resources; Infrastructure; Institution; Investments; Lysine; Mass Spectrum Analysis; Methodology; Modification; National Institute of General Medical Sciences; Oxidants; Oxidation-Reduction; Peptide Fragments; Peptides; Phase; Phosphorylation; Positioning Attribute; Post-Translational Modification Site; Post-Translational Protein Processing; Preparation; Proline; Proteins; Proteomics; Pyruvaldehyde; Reproducibility; Research; Research Personnel; Resolution; Resources; Sampling; Serine; Services; Signal Transduction; Site; Slide; South Carolina; Spatial Distribution; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Stress; Sulfonic Acids; System; Technology; Threonine; Tissue imaging; Tissues; Training; Treatment Efficacy; Tyrosine; Ubiquitin; United States National Institutes of Health; Update; base; computerized data processing; cost; crosslink; data acquisition; disulfide bond; experience; experimental study; glycation; glycosylation; imaging capabilities; improved; in vivo; instrument; instrumentation; mass spectrometric imaging; nano; new technology; novel; oxidation; programs; protein expression; response; success; therapy resistant; translational study

Proteomics Core – Project Summary The broad objective of the Proteomics Core in the SC COBRE in Oxidants, Redox Balance, and Stress Signaling (Redox COBRE) is to provide state-of-the-art, mass spectrometry (MS)-based proteomic capabilities to enable elucidation of redox signaling mechanisms underlying disease, therapeutic efficacy of cells and drugs, and therapeutic resistance. The Core provides expertise, technical assistance, instrumentation, and interpretation of analytical results for quantitative proteomic experiments and the characterization of redox-sensitive post- translational modifications. During Phase I and II, acquisition of the Orbitrap Elite ETD MS and Orbitrap Fusion Lumos ETD/UVPD MS nano-LC-MS/MS systems (NIH S10 OD010731 and S10 OD025126, PI: Lauren Ball) permitted detection of challenging modifications using complementary peptide fragmentation approaches (ETD and EThcD) and the development of advanced, quantitative proteomic workflows as needed by COBRE investigators. During Phase III, the Core will further develop and update these capabilities to reflect rapid advances in instrumentation, software, and methodologies relevant to redox proteomics. Additionally, in response to the needs of COBRE-affiliated investigators, proteomic tissue imaging capabilities using MALDI- Imaging MS (IMS) will be provided to discern the spatial distribution of enzymatically-digested peptides within tissue biospecimens on slides for the discovery of putative biomarkers and mechanisms underlying disease progression. Detection of disease-specific proteins and redox-sensitive post-translational modifications by LC- MS/MS and IMS has raised the need for targeted proteomic capabilities to verify these findings and further advance translational studies. Providing this complement of proteomic technologies will build on the successes of the Core and position the Core to establish a comprehensive, independent resource. The Core has leveraged previous investments made by the NIGMS during Phase I and II of the COBRE program, the OD and NIGMS for Shared Instrumentation Grants, the NCI Cancer Center Support Grant, and long-standing, strong institutional commitment to develop into a successful institutional resource critical to the needs of Redox COBRE investigators. At present there are 19 COBRE-affiliated users of the Proteomics Core that are PIs of 15 active NIH awards that rely on the LC-MS/MS capabilities, five of these awards also depend on IMS capabilities.

蛋白质组学核心 – 项目摘要 SC COBRE 中蛋白质组学核心在氧化剂、氧化还原平衡和应激信号传导方面的广泛目标 （Redox COBRE）旨在提供最先进的、基于质谱（MS）的蛋白质组学能力，以实现 阐明疾病背后的氧化还原信号传导机制、细胞和药物的治疗功效，以及 核心提供治疗耐药性的专业知识、技术援助、仪器和解释。 定量蛋白质组学实验的分析结果和氧化还原敏感后的表征 在第一阶段和第二阶段，收购了 Orbitrap Elite ETD MS 和 Orbitrap Fusion。 Lumos ETD/UVPD MS nano-LC-MS/MS 系统（NIH S10 OD010731 和 S10 OD025126，PI：Lauren Ball） 允许使用互补肽断裂方法（ETD）检测具有挑战性的修饰 和 EThcD），并根据 COBRE 的需要开发先进的定量蛋白质组工作流程 在第三阶段，核心将进一步开发和更新这些能力，以快速反映。 与氧化还原蛋白质组学相关的仪器、软件和方法的进步。 响应 COBRE 附属研究人员的需求，使用 MALDI 进行蛋白质组组织成像功能 将提供成像 MS (IMS) 来辨别酶消化肽的空间分布 载玻片上的组织生物样本，用于发现假定的生物标志物和疾病的机制 通过 LC- 检测疾病特异性进展蛋白和氧化还原敏感的翻译后修饰 MS/MS 和 IMS 提出了对目标蛋白质组学能力的需求，以验证这些发现并进一步 提供蛋白质组学技术的补充将建立在成功的基础上。 并将核心定位为建立全面、独立的资源。 NIGMS 在 COBRE 计划第一阶段和第二阶段期间进行的投资、OD 和 NIGMS 共享仪器补助金、NCI 癌症中心支持补助金以及长期、强大的机构 致力于发展成为对 Redox COBRE 的需求至关重要的成功的机构资源 目前，蛋白质组学核心有 19 名 COBRE 附属用户，他们是 15 名活跃的 PI。 NIH 奖项依赖于 LC-MS/MS 能力，其中五个奖项也依赖于 IMS 能力。